While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

With weight loss injectables like Ozempic and Mounjaro taking the world by storm, the diet industry is seemingly being left ...

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...

Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

The medicines regulator has urged GPs to be alert to signs of ‘misuse’ of GLP-1 receptor agonists for weight loss, such as ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42 ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...